Packaging, Labeling & Serialization
Contract packagers and serialization providers — controlling labeling accuracy, tamper evidence, and DSCSA/FMD track-and-trace across the supply chain.
What this page does not claim
A sector is an organization’s role in the value chain, not a legal category. SPEQ maps the disciplines and standards that role typically operates under; it does not determine which apply to your organization, and a count of decoded standards measures SPEQ’s coverage.
WHAT THIS SECTOR DOES
Contract packagers and serialization providers apply the labelling, tamper evidence, and unique identifiers that turn bulk product into a dispensable, traceable unit. Labelling accuracy and serialization integrity are patient-safety controls: a mislabel or a broken code can send the wrong medicine to a patient or let a falsified one into the supply chain.
REGULATORY LANDSCAPE
Packaging and labelling operations follow GMP labelling controls — FDA 21 CFR 211 subpart G and tamper-evident requirements at 211.132. Serialization is driven by the EU Falsified Medicines Directive (2011/62/EU) and its Delegated Regulation (2016/161) and by the US Drug Supply Chain Security Act (DSCSA), with GS1 standards for the data carriers, all running on validated (Annex 11 / Part 11) systems.
THE OVERSIGHT MODEL
The MAH/manufacturer owns the artwork, the specification, and release; the contract packager executes to that specification under a Quality Agreement and is accountable for reconciliation, line clearance, and serialization data exchange. Because a labelling error is a leading cause of recalls, the split of responsibility for artwork control and code generation must be explicit and tightly controlled.
WHAT QUALITY MEANS HERE
Labelling accuracy & line clearance
Artwork control, line clearance, and reconciliation that prevent mix-ups and mislabelling — a top source of packaging recalls.
Serialization & aggregation
Generating, applying, and verifying unique identifiers and aggregation data to meet FMD and DSCSA track-and-trace obligations.
Tamper evidence
Tamper-evident features and their verification (21 CFR 211.132 / FMD anti-tampering device) that let the end user trust the pack was not opened.
Validated serialization systems
Level 1–5 serialization systems validated under Annex 11 / 21 CFR Part 11, exchanging data reliably with partners and regulators.
STANDARDS SPEQ DECODES · 160
Open the full library →WHERE QUALITY FAILS
- Mislabelling or product mix-ups from weak line clearance and reconciliation
- Serialization data errors that break aggregation or regulatory reporting
- Tamper-evidence features missing or not verified
- Serialization systems that fail validation or lose data in partner exchange
KEY REGULATORY BODIES
Derived from the 160 standards SPEQ decodes for this sector.
GXP DISCIPLINES IN THIS SECTOR
Packaging, Labeling & Serialization: frequently asked questions
Reference answers on what a packaging, labeling & serialization does, what governs it, and who is accountable for quality.
What is pharmaceutical serialization?
Serialization is the application of a unique identifier to each saleable unit of medicine so it can be traced and verified through the supply chain. It is driven by the EU Falsified Medicines Directive (2011/62/EU) and its Delegated Regulation (2016/161) and by the US Drug Supply Chain Security Act (DSCSA), with GS1 standards specifying the data carriers.
Which regulations govern packaging and labelling operations?
Packaging and labelling follow GMP labelling controls — FDA 21 CFR 211 subpart G — and tamper-evident requirements at 21 CFR 211.132. Serialization adds the EU FMD, its Delegated Regulation 2016/161, and the US DSCSA, using GS1 data carriers, all running on validated systems under EU GMP Annex 11 and 21 CFR Part 11.
Who owns responsibility for labelling accuracy?
The MAH or manufacturer owns the artwork, the specification, and product release; the contract packager executes to that specification under a Quality Agreement and is accountable for reconciliation, line clearance, and serialization data exchange. Because a labelling error is a leading cause of recalls, the split of responsibility for artwork control and code generation must be explicit and tightly controlled.